Astrazeneca gives Valeant Pharma development rights for inflammation drug for an upfront $100 million

1 September 2015

Anglo-Swedish drug major AstraZeneca (LSE: AZN) on Tuesday said it has agreed to grant Valeant Pharmaceuticals (NYSE: VRX) an exclusive license to develop and market its drug candidate, brodalumab, to treat inflammation for an upfront payment of $100 million.

Under the terms of the agreement, Valeant will also pay additional pre-launch milestones of up to $170 million and further sales related milestone payments of up to $175 million following the launch. AstraZeneca and Valeant will share profits following the approval for the drug.

Regulatory submission in the USA and European Union for brodalumab to treat moderate-to-severe psoriasis is planned for the fourth quarter of 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK